- Home
- MBC vs VRDN Comparison
MBC vs VRDN Comparison
Compare MBC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- VRDN
- Stock Information
- Founded
- MBC 1954
- VRDN 2006
- Country
- MBC United States
- VRDN United States
- Employees
- MBC N/A
- VRDN N/A
- Industry
- MBC Agricultural Chemicals
- VRDN Medical Specialities
- Sector
- MBC Industrials
- VRDN Health Care
- Exchange
- MBC Nasdaq
- VRDN Nasdaq
- Market Cap
- MBC 1.8B
- VRDN 1.6B
- IPO Year
- MBC N/A
- VRDN N/A
- Fundamental
- Price
- MBC $11.00
- VRDN $11.02
- Analyst Decision
- MBC Strong Buy
- VRDN Buy
- Analyst Count
- MBC 1
- VRDN 12
- Target Price
- MBC $19.00
- VRDN $36.44
- AVG Volume (30 Days)
- MBC 980.7K
- VRDN 840.6K
- Earning Date
- MBC 05-06-2025
- VRDN 05-07-2025
- Dividend Yield
- MBC N/A
- VRDN N/A
- EPS Growth
- MBC N/A
- VRDN N/A
- EPS
- MBC 0.96
- VRDN N/A
- Revenue
- MBC $2,700,400,000.00
- VRDN $302,000.00
- Revenue This Year
- MBC $5.06
- VRDN N/A
- Revenue Next Year
- MBC $5.11
- VRDN $20,553.29
- P/E Ratio
- MBC $11.89
- VRDN N/A
- Revenue Growth
- MBC N/A
- VRDN N/A
- 52 Week Low
- MBC $10.95
- VRDN $10.83
- 52 Week High
- MBC $20.67
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- MBC 33.11
- VRDN 24.46
- Support Level
- MBC $11.64
- VRDN $14.03
- Resistance Level
- MBC $12.73
- VRDN $15.91
- Average True Range (ATR)
- MBC 0.54
- VRDN 0.83
- MACD
- MBC -0.08
- VRDN -0.29
- Stochastic Oscillator
- MBC 12.69
- VRDN 3.74
Stock Price Comparison Chart: MBC vs VRDN
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.